
Alexion Pharmaceuticals, Inc. Revenue | ALXN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Alexion Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 6.07 B | 4.99 B | 4.13 B | 3.55 B | 3.08 B | 2.6 B | 2.23 B | 1.55 B | 1.13 B | 783 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.07 B | 783 M | 3.01 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Omeros Corporation
OMER
|
10.6 M | $ 14.67 | 4.24 % | $ 932 M | ||
|
Lineage Cell Therapeutics
LCTX
|
14.6 M | $ 0.84 | 3.54 % | $ 193 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
268 M | $ 298.84 | 1.71 % | $ 5.78 B | ||
|
Mustang Bio
MBIO
|
-50 K | $ 0.38 | -2.31 % | $ 1.87 M | ||
|
Adagene
ADAG
|
7.67 M | $ 1.78 | 20.27 % | $ 105 M | ||
|
Puma Biotechnology
PBYI
|
228 M | $ 7.22 | 1.12 % | $ 361 M | ||
|
Denali Therapeutics
DNLI
|
331 M | $ 18.41 | 2.25 % | $ 3.18 B | ||
|
Amarin Corporation plc
AMRN
|
214 M | $ 11.25 | -0.18 % | $ 4.67 B | ||
|
ImmuCell Corporation
ICCC
|
27.6 M | $ 11.2 | -1.15 % | $ 101 M | ||
|
Editas Medicine
EDIT
|
40.5 M | $ 1.77 | -3.29 % | $ 157 M | ||
|
Agios Pharmaceuticals
AGIO
|
54 M | $ 29.7 | -0.64 % | $ 1.72 B | ||
|
Pfizer
PFE
|
62.6 B | $ 28.06 | -1.46 % | $ 159 B | ||
|
Equillium
EQ
|
41.1 M | $ 1.1 | -9.5 % | $ 63 M | ||
|
Black Diamond Therapeutics
BDTX
|
70 M | $ 1.43 | -1.04 % | $ 81.3 M | ||
|
Abeona Therapeutics
ABEO
|
5.82 M | $ 2.73 | 4.81 % | $ 145 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.07 B | $ 18.0 | -1.77 % | $ 3.03 B | ||
|
Atossa Therapeutics
ATOS
|
1.76 K | $ 1.8 | -5.26 % | $ 15.5 M | ||
|
Cleveland BioLabs, Inc.
CBLI
|
263 K | - | -7.31 % | $ 49 M | ||
|
Pliant Therapeutics
PLRX
|
1.58 M | $ 0.66 | 0.38 % | $ 40.5 M | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
13.2 M | - | - | $ 1.77 B | ||
|
ADC Therapeutics SA
ADCT
|
81.4 M | $ 1.33 | -1.48 % | $ 169 M | ||
|
Harmony Biosciences Holdings
HRMY
|
868 M | $ 33.1 | 0.29 % | $ 1.9 B | ||
|
Ardelyx
ARDX
|
407 M | $ 3.15 | -1.1 % | $ 759 M | ||
|
Akebia Therapeutics
AKBA
|
236 M | $ 0.41 | 2.22 % | $ 105 M | ||
|
Alector
ALEC
|
21 M | $ 2.56 | 1.17 % | $ 264 M | ||
|
ALX Oncology Holdings
ALXO
|
1.18 M | $ 0.97 | -3.11 % | $ 52 M | ||
|
Amneal Pharmaceuticals
AMRX
|
3.02 B | $ 21.81 | 3.27 % | $ 6.83 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
14.1 M | $ 4.12 | 1.6 % | $ 789 M | ||
|
Agenus
AGEN
|
114 M | $ 6.39 | 2.82 % | $ 190 M | ||
|
AbCellera Biologics
ABCL
|
75.1 M | $ 11.0 | -0.32 % | $ 3.29 B | ||
|
Aptevo Therapeutics
APVO
|
3.11 M | $ 0.45 | -3.45 % | $ 142 K | ||
|
Aligos Therapeutics
ALGS
|
2.19 M | $ 1.3 | -4.41 % | $ 12.9 M | ||
|
Aclaris Therapeutics
ACRS
|
7.83 M | $ 3.48 | 2.81 % | $ 427 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
277 M | $ 28.47 | -0.07 % | $ 4.32 B | ||
|
Biofrontera AG
BFRA
|
30.3 M | - | -8.24 % | $ 105 M | ||
|
Pulmatrix
PULM
|
7.81 M | $ 1.34 | -2.19 % | $ 4.89 B | ||
|
Intellia Therapeutics
NTLA
|
67.7 M | $ 9.68 | -1.07 % | $ 1.05 B | ||
|
Pharming Group N.V.
PHAR
|
186 M | $ 12.48 | 3.51 % | $ 8.6 B | ||
|
Catabasis Pharmaceuticals, Inc.
CATB
|
500 K | - | -6.97 % | $ 657 M | ||
|
Capricor Therapeutics
CAPR
|
22.3 M | $ 8.04 | -4.4 % | $ 374 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 29.66 | 1.91 % | $ 1.39 B | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
326 B | $ 14.98 | 1.28 % | $ 12.5 B | ||
|
China Biologic Products Holdings, Inc.
CBPO
|
524 M | - | 1.68 % | $ 4.65 B |